Tigermed Reports Impressive Growth in 2025 Annual Results with Record Revenue Hangzhou Tigermed Consulting Co. Ltd. announces substantial revenue growth for 2025, signaling a strong future for its global biopharmaceutical services.

Tigermed Reports Impressive Growth in 2025 Annual Results with Record Revenue #China #biopharmaceuticals #Hangzhou #Clinical_Trials #Tigermed

Tigermed Reports Impressive Annual Results for 2025 Showing Strong Growth in Clinical Research Tigermed Consulting announces its annual results for 2025, showcasing a remarkable growth in revenue and significant advancements in R&D solutions.

Tigermed Reports Impressive Annual Results for 2025 Showing Strong Growth in Clinical Research #China #biopharmaceuticals #Hangzhou #Clinical_Research #Tigermed

Tigermed Selected as One of Forbes Top Flagship Brands for 2025 Tigermed has been recognized as a leading company on Forbes’ '2025 Go-International Flagship Brands' list, highlighting its global influence.

Tigermed Selected as One of Forbes Top Flagship Brands for 2025 #China #Forbes #Hangzhou #Biopharmaceutical #Tigermed

Tigermed Named Among Top 30 in 2025 Forbes China Go-International Brands In a significant achievement, Tigermed has been recognized as one of the Top 30 companies in Forbes China's 2025 Go-International Flagship Brands list.

Tigermed Named Among Top 30 in 2025 Forbes China Go-International Brands #China #Hangzhou #Forbes_China #Tigermed #Go-International

Tigermed Achieves Prestigious MSCI ESG AAA Rating, Leading Industry Sustainability Tigermed has proudly earned an MSCI ESG AAA rating, reflecting its commitment to sustainability and social responsibility, marking a key milestone for the company.

Tigermed Achieves Prestigious MSCI ESG AAA Rating, Leading Industry Sustainability #China #Hangzhou #ESG #MSCI #Tigermed

Tigermed Achieves Highest MSCI ESG Rating: AAA Recognition Tigermed proudly announces its AAA MSCI ESG rating, highlighting its commitment to sustainable business practices and leadership in environmental, social, and governance initiatives.

Tigermed Achieves Highest MSCI ESG Rating: AAA Recognition #China #Hangzhou #ESG #MSCI #Tigermed

Tigermed Expands Global Reach with Strategic Acquisition of Micron in Japan Tigermed, a global leader in clinical research solutions, has finalized the acquisition of Micron, a prominent Japanese CRO, enhancing its medical imaging capabilities in Asia.

Tigermed Expands Global Reach with Strategic Acquisition of Micron in Japan #China #Japan #Tokyo #Tigermed #Micron_CRO

Tigermed Successfully Completes the Acquisition of Japanese CRO Micron Tigermed announces the completion of acquiring Micron, a leading Japanese Contract Research Organization specializing in clinical trials and medical imaging services.

Tigermed Successfully Completes the Acquisition of Japanese CRO Micron #China #Tokyo #Micron #CRO #Tigermed

Teddy Laboratory and LabConnect Partner to Innovate Laboratory Services and Drug Development Teddy Laboratory has signed a strategic alliance with LabConnect to enhance global drug development by combining their laboratory services.

Teddy Laboratory and LabConnect Partner to Innovate Laboratory Services and Drug Development #USA #LabConnect #Johnson_City #Teddy_Laboratory #Tigermed